Inotuzumab ozogamicin in combination with low-intensity chemotherapy (mini-HCVD) with or without blinatumomab vs standard intensive chemotherapy (HCVAD) as frontline therapy for older patients with Philadelphia chromosome-negative acute lymphoblastic leukemia: A propensity score analysis
Cancer Aug 01, 2019
Jabbour EJ, Sasaki K, Ravandi F, et al. - In this analysis of older patients with newly diagnosed, Philadelphia chromosome (Ph)-negative acute lymphoblastic leukemia, patients who received a combination of inotuzumab ozogamicin plus low-intensity chemotherapy (mini–hyperfractionated cyclophosphamide, vincristine, and dexamethasone [mini-HCVD]) with or without blinatumomab were compared with those who received the standard, intensive, hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (HCVAD) regimen regarding their outcome. Researchers included 38 patients in each cohort following propensity score matching. Outcomes suggest that in these patients, the combination of inotuzumab ozogamicin plus mini-HCVD with or without blinatumomab was safe and efficacious and resulted in a better outcome when compared with standard HCVAD chemotherapy.
Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
-
Exclusive Write-ups & Webinars by KOLs
-
Daily Quiz by specialty
-
Paid Market Research Surveys
-
Case discussions, News & Journals' summaries